Symbols / PSTV $0.26 -1.42%
PSTV Chart
About
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests comprising the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Houston, Texas.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 45.84M |
| Enterprise Value | 36.93M | Income | -22.39M | Sales | 5.21M |
| Book/sh | 0.03 | Cash/sh | 0.05 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -2.86 | PEG | — |
| P/S | 8.79 | P/B | 8.86 | P/C | — |
| EV/EBITDA | -2.49 | EV/Sales | 7.08 | Quick Ratio | 0.73 |
| Current Ratio | 1.23 | Debt/Eq | 20.55 | LT Debt/Eq | — |
| EPS (ttm) | -0.29 | EPS next Y | -0.09 | EPS Growth | — |
| Revenue Growth | -3.20% | Earnings | 2026-03-04 | ROA | -83.29% |
| ROE | — | ROIC | — | Gross Margin | -60.73% |
| Oper. Margin | -4.20% | Profit Margin | 0.00% | Shs Outstand | 178.37M |
| Shs Float | 158.56M | Short Float | 11.31% | Short Ratio | 2.52 |
| Short Interest | — | 52W High | 2.08 | 52W Low | 0.16 |
| Beta | 0.83 | Avg Volume | 9.69M | Volume | 1.96M |
| Target Price | $5.30 | Recom | Strong_buy | Prev Close | $0.26 |
| Price | $0.26 | Change | -1.42% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$5.30
Mean price target
2. Current target
$0.25
Latest analyst target
3. DCF / Fair value
$-1.37
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.25
Low
$1.00
High
$19.00
Mean
$5.30
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-23 | main | HC Wainwright & Co. | Buy → Buy | $1 |
| 2026-01-22 | main | D. Boral Capital | Buy → Buy | $4 |
| 2026-01-08 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-12-11 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-12-01 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-11-21 | main | Ascendiant Capital | Buy → Buy | $19 |
| 2025-11-20 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-11-03 | main | HC Wainwright & Co. | Buy → Buy | $2 |
| 2025-10-31 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-10-21 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-10-06 | main | Ascendiant Capital | Buy → Buy | $21 |
| 2025-09-25 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-09-22 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-09-18 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-09-03 | up | D. Boral Capital | Hold → Buy | $5 |
| 2025-08-18 | main | Maxim Group | Buy → Buy | $3 |
| 2025-06-27 | main | HC Wainwright & Co. | Buy → Buy | $3 |
| 2025-06-25 | main | D. Boral Capital | Hold → Hold | $9 |
| 2025-06-05 | main | Ascendiant Capital | Buy → Buy | $21 |
| 2025-05-05 | down | D. Boral Capital | Buy → Hold | — |
- $PSTV stock is down 16% today. Here's what we see in our data. - Quiver Quantitative Fri, 13 Mar 2026 19
- Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Plus Therapeutics (PSTV) - The Globe and Mail ue, 17 Mar 2026 13
- Inside Plus Therapeutics' 2026 brain cancer drug and spinal fluid test plans - Stock Titan hu, 12 Mar 2026 20
- Plus Therapeutics (PSTV) Reports Break-Even Earnings for Q4 - Yahoo Finance hu, 12 Mar 2026 23
- Analysts Offer Insights on Healthcare Companies: Aclaris Therapeutics (ACRS) and Plus Therapeutics (PSTV) - The Globe and Mail ue, 17 Mar 2026 10
- Plus Therapeutics (PSTV) CFO granted RSUs and stock options package - Stock Titan Fri, 27 Feb 2026 08
- Plus Therapeutics (PSTV) Soars 40% as Firm Seals Partnership with United Healthcare - Yahoo Finance Fri, 26 Sep 2025 07
- No approved drugs for this cancer: FDA shapes path for a possible new option - Stock Titan hu, 08 Jan 2026 08
- $PSTV stock is down 9% today. Here's what we see in our data. - Quiver Quantitative hu, 22 Jan 2026 08
- Plus Therapeutics (PSTV) widens 2025 loss but strengthens cash and CNS programs - Stock Titan hu, 12 Mar 2026 20
- Plus Therapeutics Sets 2026 Virtual Annual Stockholder Meeting - The Globe and Mail Fri, 13 Mar 2026 21
- CNS cancer-focused company raises $15M in stock and warrant sale - Stock Titan Wed, 14 Jan 2026 08
- Plus Therapeutics Stock (PSTV) Opinions on FDA Meeting for REYOBIQ™ Approval - Quiver Quantitative hu, 08 Jan 2026 08
- Investors get Plus Therapeutics business update in Jan. 22 webcast - Stock Titan Wed, 21 Jan 2026 08
- New AMA code tracks REYOBIQ therapy in aggressive brain cancers - Stock Titan Wed, 25 Feb 2026 08
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership | Value |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 159681 | — | — | HEDRICK MARC HAMILTON | Chief Executive Officer | — | 2025-12-31 00:00:00 | D | nan |
| 1 | 38323 | — | — | SIMS ANDREW JOHN HUGH MACINTYRE | Chief Financial Officer | — | 2025-12-31 00:00:00 | D | nan |
| 2 | 20000 | — | Purchase at price 0.51 per share. | SIMS ANDREW JOHN HUGH MACINTYRE | Chief Financial Officer | — | 2025-11-04 00:00:00 | D | 10200.0 |
| 3 | 159681 | — | — | HEDRICK MARC HAMILTON | Chief Executive Officer | — | 2025-10-01 00:00:00 | D | nan |
| 4 | 38323 | — | — | SIMS ANDREW JOHN HUGH MACINTYRE | Chief Financial Officer | — | 2025-10-01 00:00:00 | D | nan |
| 5 | 110000 | — | Purchase at price 0.49 per share. | LENK ROBERT P | Director | — | 2025-08-22 00:00:00 | D | 53779.0 |
| 6 | 4000 | — | Purchase at price 1.50 per share. | HAWKINS RICHARD JAMES | Director | — | 2024-09-13 00:00:00 | D | 5996.0 |
| 7 | 6285 | — | Purchase at price 1.35 per share. | HAWKINS RICHARD JAMES | Director | — | 2024-09-12 00:00:00 | D | 8512.0 |
| 8 | 12500 | — | Purchase at price 1.35 per share. | PETERSEN GREGORY B | Director | — | 2024-09-11 00:00:00 | D | 16875.0 |
| 9 | 5000 | — | Purchase at price 1.34 per share. | CLOWES HOWARD | Director | — | 2024-09-11 00:00:00 | D | 6681.0 |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -15.70M | -14.04M | -12.29M | -18.95M |
| TotalUnusualItems | -2.63M | 5.65M | 1.00K | -60.00K |
| TotalUnusualItemsExcludingGoodwill | -2.63M | 5.65M | 1.00K | -60.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -22.39M | -12.98M | -13.32M | -20.27M |
| ReconciledDepreciation | 445.00K | 872.00K | 628.00K | 619.00K |
| EBITDA | -18.33M | -8.38M | -12.29M | -18.95M |
| EBIT | -18.78M | -9.25M | -12.92M | -19.56M |
| NetInterestIncome | -3.49M | -3.45M | 5.00K | -564.00K |
| InterestExpense | 3.61M | 3.72M | 395.00K | 711.00K |
| InterestIncome | 116.00K | 273.00K | 400.00K | 147.00K |
| NormalizedIncome | -19.75M | -18.63M | -13.32M | -20.27M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -22.39M | -12.98M | -13.32M | -20.27M |
| TotalExpenses | 15.30M | 14.70M | 13.32M | 19.71M |
| TotalOperatingIncomeAsReported | -15.30M | -14.70M | -13.32M | -19.71M |
| DilutedAverageShares | 77.80M | 7.70M | 3.14M | 1.75M |
| BasicAverageShares | 77.80M | 6.64M | 3.14M | 1.75M |
| DilutedEPS | -0.29 | -2.34 | -4.24 | -11.55 |
| BasicEPS | -0.29 | -1.95 | -4.24 | -11.55 |
| DilutedNIAvailtoComStockholders | -22.39M | -18.02M | -13.32M | -20.27M |
| AverageDilutionEarnings | 0.00 | -5.05M | ||
| NetIncomeCommonStockholders | -22.39M | -12.98M | -13.32M | -20.27M |
| NetIncome | -22.39M | -12.98M | -13.32M | -20.27M |
| NetIncomeIncludingNoncontrollingInterests | -22.39M | -12.98M | -13.32M | -20.27M |
| NetIncomeContinuousOperations | -22.39M | -12.98M | -13.32M | -20.27M |
| PretaxIncome | -22.39M | -12.98M | -13.32M | -20.27M |
| OtherIncomeExpense | -3.60M | 5.17M | 1.00K | -60.00K |
| OtherNonOperatingIncomeExpenses | -964.00K | -486.00K | 1.00K | 6.00K |
| SpecialIncomeCharges | 0.00 | -66.00K | ||
| GainOnSaleOfPPE | 0.00 | -66.00K | ||
| GainOnSaleOfSecurity | -2.63M | 5.65M | 1.00K | 6.00K |
| NetNonOperatingInterestIncomeExpense | -3.49M | -3.45M | 5.00K | -564.00K |
| InterestExpenseNonOperating | 3.61M | 3.72M | 395.00K | 711.00K |
| InterestIncomeNonOperating | 116.00K | 273.00K | 400.00K | 147.00K |
| OperatingIncome | -15.30M | -14.70M | -13.32M | -19.71M |
| OperatingExpense | 15.30M | 14.70M | 13.32M | 19.71M |
| OtherOperatingExpenses | -5.21M | -5.82M | -4.91M | -224.00K |
| ResearchAndDevelopment | 8.38M | 10.58M | 9.69M | 9.70M |
| SellingGeneralAndAdministration | 12.13M | 9.94M | 8.54M | 10.24M |
| GeneralAndAdministrativeExpense | 12.13M | 9.94M | 8.54M | 10.24M |
| OtherGandA | 12.13M | 9.94M | 8.54M | 10.24M |
| SalariesAndWages | 519.00K | 531.00K | ||
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | |
|---|---|---|---|---|
| TreasurySharesNumber | 258.43K | 258.43K | 78.56K | |
| PreferredSharesNumber | 325.00 | 325.00 | 325.00 | 325.00 |
| OrdinarySharesNumber | 138.90M | 5.90M | 4.44M | 2.24M |
| ShareIssued | 139.16M | 6.15M | 4.52M | 2.24M |
| NetDebt | 3.22M | |||
| TotalDebt | 821.00K | 3.37M | 4.18M | 5.64M |
| TangibleBookValue | 3.29M | -9.79M | -1.76M | 5.98M |
| InvestedCapital | 4.75M | -5.66M | 2.63M | 11.84M |
| WorkingCapital | 2.86M | -10.29M | -893.00K | 9.96M |
| NetTangibleAssets | 3.29M | -9.79M | -1.76M | 5.98M |
| CapitalLeaseObligations | 71.00K | 75.00K | 205.00K | 251.00K |
| CommonStockEquity | 4.00M | -8.95M | -1.35M | 6.45M |
| TotalCapitalization | 4.00M | -8.95M | -1.35M | 10.23M |
| TotalEquityGrossMinorityInterest | 4.00M | -8.95M | -1.35M | 6.45M |
| StockholdersEquity | 4.00M | -8.95M | -1.35M | 6.45M |
| TreasuryStock | 500.00K | 500.00K | 126.00K | 0.00 |
| RetainedEarnings | -515.87M | -493.48M | -480.50M | -467.19M |
| AdditionalPaidInCapital | 520.22M | 485.02M | 479.27M | 473.63M |
| CapitalStock | 139.00K | 6.00K | 5.00K | 2.00K |
| CommonStock | 139.00K | 6.00K | 5.00K | 2.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 12.33M | 15.58M | 12.74M | 17.42M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 15.00K | 31.00K | 2.01M | 5.57M |
| DerivativeProductLiabilities | 0.00 | 1.00K | ||
| NonCurrentDeferredLiabilities | 0.00 | 1.92M | 1.64M | 0.00 |
| NonCurrentDeferredRevenue | 0.00 | 1.92M | 1.64M | |
| LongTermDebtAndCapitalLeaseObligation | 15.00K | 31.00K | 85.00K | 3.93M |
| LongTermCapitalLeaseObligation | 15.00K | 31.00K | 85.00K | 141.00K |
| LongTermDebt | 3.79M | 5.00M | ||
| CurrentLiabilities | 12.31M | 15.55M | 10.73M | 11.85M |
| OtherCurrentLiabilities | 4.66M | 122.00K | ||
| CurrentDeferredLiabilities | 927.00K | 927.00K | 0.00 | |
| CurrentDeferredRevenue | 927.00K | 927.00K | 0.00 | |
| CurrentDebtAndCapitalLeaseObligation | 806.00K | 3.34M | 4.10M | 1.72M |
| CurrentCapitalLeaseObligation | 56.00K | 44.00K | 120.00K | 110.00K |
| CurrentDebt | 750.00K | 3.29M | 3.98M | 1.61M |
| OtherCurrentBorrowings | 3.98M | 1.61M | 1.61M | |
| LineOfCredit | 750.00K | 3.29M | 3.98M | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 421.00K | 356.00K | 370.00K | 325.00K |
| PayablesAndAccruedExpenses | 5.50M | 10.93M | 6.26M | 9.81M |
| CurrentAccruedExpenses | 2.22M | 1.46M | 1.50M | 1.45M |
| InterestPayable | 0.00 | 117.00K | 0.00 | |
| Payables | 3.28M | 9.47M | 4.76M | 8.36M |
| AccountsPayable | 3.28M | 9.47M | 4.76M | 8.36M |
| TotalAssets | 16.32M | 6.63M | 11.39M | 23.87M |
| TotalNonCurrentAssets | 1.16M | 1.37M | 1.55M | 2.05M |
| OtherNonCurrentAssets | 123.00K | 12.00K | 32.00K | 12.00K |
| GoodwillAndOtherIntangibleAssets | 705.00K | 841.00K | 414.00K | 466.00K |
| OtherIntangibleAssets | 333.00K | 469.00K | 42.00K | 94.00K |
| Goodwill | 372.00K | 372.00K | 372.00K | 372.00K |
| NetPPE | 327.00K | 521.00K | 1.11M | 1.57M |
| AccumulatedDepreciation | -3.33M | -3.14M | -2.54M | -1.96M |
| GrossPPE | 3.66M | 3.66M | 3.64M | 3.53M |
| Leases | 1.81M | 1.81M | 1.81M | 1.81M |
| OtherProperties | 70.00K | 73.00K | 202.00K | 248.00K |
| MachineryFurnitureEquipment | 1.78M | 1.78M | 1.63M | 1.47M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 15.17M | 5.26M | 9.83M | 21.82M |
| OtherCurrentAssets | 7.00K | |||
| CurrentDeferredAssets | 394.00K | 436.00K | 234.00K | |
| RestrictedCash | 4.50M | 0.00 | ||
| PrepaidAssets | 1.34M | 646.00K | 1.05M | 3.70M |
| Receivables | 322.00K | 571.00K | 0.00 | 7.00K |
| OtherReceivables | 322.00K | 571.00K | 7.00K | |
| CashCashEquivalentsAndShortTermInvestments | 8.61M | 3.61M | 8.55M | 18.12M |
| OtherShortTermInvestments | 4.36M | 3.53M | 0.00 | |
| CashAndCashEquivalents | 4.26M | 76.00K | 8.55M | 18.12M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -20.84M | -11.24M | -13.01M | -13.73M |
| RepurchaseOfCapitalStock | 0.00 | -374.00K | -126.00K | 0.00 |
| RepaymentOfDebt | -7.00M | -4.00M | -1.61M | -1.61M |
| IssuanceOfDebt | 4.49M | 3.29M | 0.00 | |
| IssuanceOfCapitalStock | 38.54M | 7.26M | 5.53M | 15.83M |
| CapitalExpenditure | -67.00K | -691.00K | -160.00K | -759.00K |
| InterestPaidSupplementalData | 0.00 | 32.00K | 222.00K | 327.00K |
| EndCashPosition | 8.76M | 76.00K | 8.55M | 18.12M |
| BeginningCashPosition | 76.00K | 8.55M | 18.12M | 18.40M |
| ChangesInCash | 8.68M | -8.48M | -9.57M | -280.00K |
| FinancingCashFlow | 30.31M | 6.19M | 3.44M | 13.45M |
| CashFlowFromContinuingFinancingActivities | 30.31M | 6.19M | 3.44M | 13.45M |
| NetOtherFinancingCharges | -5.72M | -348.00K | -773.00K | |
| ProceedsFromStockOptionExercised | 0.00 | 2.02M | ||
| NetCommonStockIssuance | 38.54M | 6.89M | 5.40M | 15.83M |
| CommonStockPayments | 0.00 | -374.00K | -126.00K | 0.00 |
| CommonStockIssuance | 38.54M | 7.26M | 5.53M | 15.83M |
| NetIssuancePaymentsOfDebt | -2.51M | -704.00K | -1.61M | -1.61M |
| NetShortTermDebtIssuance | -2.54M | 3.29M | 0.00 | |
| ShortTermDebtPayments | -3.29M | 0.00 | ||
| ShortTermDebtIssuance | 750.00K | 3.29M | 0.00 | |
| NetLongTermDebtIssuance | 35.00K | -4.00M | -1.61M | -1.61M |
| LongTermDebtPayments | -3.70M | -4.00M | -1.61M | -1.61M |
| LongTermDebtIssuance | 3.74M | 0.00 | ||
| InvestingCashFlow | -854.00K | -4.11M | -160.00K | -759.00K |
| CashFlowFromContinuingInvestingActivities | -854.00K | -4.11M | -160.00K | -759.00K |
| NetOtherInvestingChanges | -250.00K | |||
| NetInvestmentPurchaseAndSale | -817.00K | -3.42M | 0.00 | |
| SaleOfInvestment | 8.54M | 12.17M | 0.00 | |
| PurchaseOfInvestment | -9.35M | -15.59M | 0.00 | |
| NetIntangiblesPurchaseAndSale | 0.00 | -545.00K | 0.00 | -250.00K |
| PurchaseOfIntangibles | 0.00 | -545.00K | 0.00 | -250.00K |
| NetPPEPurchaseAndSale | -37.00K | -146.00K | -160.00K | -509.00K |
| SaleOfPPE | 30.00K | 0.00 | 0.00 | 62.00K |
| PurchaseOfPPE | -67.00K | -146.00K | -160.00K | -509.00K |
| OperatingCashFlow | -20.77M | -10.55M | -12.85M | -12.97M |
| CashFlowFromContinuingOperatingActivities | -20.77M | -10.55M | -12.85M | -12.97M |
| ChangeInWorkingCapital | -6.04M | 3.22M | -1.12M | 5.60M |
| ChangeInOtherWorkingCapital | -997.00K | 281.00K | 1.64M | |
| ChangeInOtherCurrentLiabilities | 93.00K | -130.00K | -117.00K | -129.00K |
| ChangeInOtherCurrentAssets | -763.00K | 218.00K | 2.40M | -2.37M |
| ChangeInPayablesAndAccruedExpense | -5.62M | 4.70M | -3.68M | 6.45M |
| ChangeInReceivables | 249.00K | -571.00K | 0.00 | 0.00 |
| ChangesInAccountReceivables | 0.00 | |||
| OtherNonCashItems | 3.06M | 3.54M | 382.00K | 388.00K |
| StockBasedCompensation | 1.54M | 550.00K | 569.00K | 606.00K |
| UnrealizedGainLossOnInvestmentSecurities | -1.00K | -6.00K | ||
| AssetImpairmentCharge | 117.00K | 93.00K | 24.00K | |
| AmortizationOfSecurities | -9.00K | -111.00K | 0.00 | |
| DepreciationAmortizationDepletion | 445.00K | 872.00K | 628.00K | 619.00K |
| DepreciationAndAmortization | 445.00K | 872.00K | 628.00K | 619.00K |
| AmortizationCashFlow | 100.00K | 100.00K | 100.00K | |
| AmortizationOfIntangibles | 100.00K | 100.00K | 100.00K | |
| Depreciation | 600.00K | 600.00K | 500.00K | |
| OperatingGainsLosses | 2.62M | -5.65M | 2.00K | 66.00K |
| GainLossOnInvestmentSecurities | 2.63M | -5.65M | ||
| GainLossOnSaleOfPPE | 0.00 | 2.00K | 0.00 | 66.00K |
| NetIncomeFromContinuingOperations | -22.39M | -12.98M | -13.32M | -20.27M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for PSTV
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|